Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Raw Materials (2016 - 2021)

Guided Therapeutics' Raw Materials history spans 8 years, with the latest figure at $1.3 million for Q1 2021.

  • For Q1 2021, Raw Materials rose 63.09% year-over-year to $1.3 million; the TTM value through Mar 2021 reached $1.3 million, up 63.09%, while the annual FY2020 figure was $1.3 million, 63.38% up from the prior year.
  • Raw Materials for Q1 2021 was $1.3 million at Guided Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.3 million in Q1 2021 and bottomed at $781000.0 in Q1 2019.
  • The 5-year median for Raw Materials is $789000.0 (2017), against an average of $844294.1.
  • The largest annual shift saw Raw Materials decreased 7.77% in 2017 before it skyrocketed 63.38% in 2020.
  • A 5-year view of Raw Materials shows it stood at $789000.0 in 2017, then decreased by 0.76% to $783000.0 in 2018, then dropped by 0.26% to $781000.0 in 2019, then surged by 63.38% to $1.3 million in 2020, then grew by 0.08% to $1.3 million in 2021.
  • Per Business Quant, the three most recent readings for GTHP's Raw Materials are $1.3 million (Q1 2021), $1.3 million (Q4 2020), and $782000.0 (Q3 2020).